home / stock / nnvc / nnvc quote
Last: | $1.78 |
---|---|
Change Percent: | 0.54% |
Open: | $1.84 |
Close: | $1.78 |
High: | $1.88 |
Low: | $1.74 |
Volume: | 208,535 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.78 | $1.84 | $1.78 | $1.88 | $1.74 | 208,535 | 07-02-2024 |
$1.85 | $1.75 | $1.85 | $1.85 | $1.7 | 347,911 | 07-01-2024 |
$1.72 | $1.75 | $1.72 | $1.78 | $1.65 | 316,365 | 06-28-2024 |
$1.73 | $1.8 | $1.73 | $1.831 | $1.73 | 218,809 | 06-27-2024 |
$1.82 | $1.83 | $1.82 | $1.95 | $1.78 | 521,193 | 06-26-2024 |
$1.91 | $1.94 | $1.91 | $2.04 | $1.767 | 488,498 | 06-25-2024 |
$1.92 | $2.04 | $1.92 | $2.07 | $1.9 | 405,769 | 06-24-2024 |
$1.82 | $2.02 | $1.82 | $2.03 | $1.78 | 151,347 | 06-21-2024 |
$2.03 | $1.76 | $2.03 | $2.11 | $1.75 | 533,483 | 06-20-2024 |
$1.64 | $1.87 | $1.64 | $1.9276 | $1.63 | 228,539 | 06-19-2024 |
$1.64 | $1.87 | $1.64 | $1.9276 | $1.63 | 228,539 | 06-18-2024 |
$1.9 | $1.88 | $1.9 | $1.9796 | $1.84 | 233,665 | 06-17-2024 |
$1.9 | $2.55 | $1.9 | $2.579 | $1.88 | 691,104 | 06-14-2024 |
$2.58 | $2.49 | $2.58 | $2.77 | $2.48 | 525,127 | 06-13-2024 |
$2.45 | $3.35 | $2.45 | $3.35 | $2.36 | 748,084 | 06-12-2024 |
$3.31 | $3.28 | $3.31 | $3.41 | $3.1201 | 648,341 | 06-11-2024 |
$3.03 | $2.71 | $3.03 | $3.59 | $2.67 | 967,382 | 06-10-2024 |
$2.67 | $2.65 | $2.67 | $2.74 | $2.62 | 182,914 | 06-07-2024 |
$2.65 | $2.5 | $2.65 | $2.95 | $2.4 | 1,187,935 | 06-06-2024 |
$2.43 | $2.45 | $2.43 | $2.47 | $2.3601 | 188,669 | 06-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
SHELTON, CT / ACCESSWIRE / July 1, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical-stage global leader in broad-spectrum antiviral nanomedicines, elaborates on its current assets and plans towards becoming a successful pharmaceutical company intending to revolutioni...
--News Direct-- NanoViricides CEO Dr Anil Diwan joined Steve Darling from Proactive to share promising news about the company's ultra-broad-spectrum antiviral, NV-387. The antiviral was found to be effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse mod...
SHELTON, CT / ACCESSWIRE / June 24, 2024 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, comments that the ultra-broad-spectrum antiviral NV-387 could be an important weapon against bird flu H5N1 viruses. Nan...